Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
10x Genomics (TXG) had Return on Tangible Equity of -5.00% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$154.88M |
|
$-34.36M |
|
$49.44M |
|
$105.44M |
|
$194.21M |
|
$-39.33M |
|
$5.82M |
|
$-33.51M |
|
$-33.51M |
|
$-34.36M |
|
$-34.36M |
|
$-34.36M |
|
$-34.36M |
|
$-39.33M |
|
$-29.51M |
|
122.61M |
|
122.61M |
|
$-0.28 |
|
$-0.28 |
|
| Balance Sheet Financials | |
$579.73M |
|
$246.09M |
|
$323.66M |
|
$903.39M |
|
$107.90M |
|
-- |
|
$88.60M |
|
$196.50M |
|
$706.89M |
|
$687.19M |
|
$706.89M |
|
123.13M |
|
| Cash Flow Statement Financials | |
$34.35M |
|
$-1.89M |
|
$0.42M |
|
$344.07M |
|
$377.06M |
|
$32.99M |
|
$31.08M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.37 |
|
-- |
|
-- |
|
-- |
|
-- |
|
68.08% |
|
-25.39% |
|
-25.39% |
|
-- |
|
-21.63% |
|
-22.18% |
|
$32.46M |
|
-- |
|
-- |
|
-- |
|
0.17 |
|
0.66 |
|
2.95 |
|
30.54 |
|
-4.86% |
|
|
Return on Tangible Equity |
-5.00% |
-3.80% |
|
-4.86% |
|
$5.74 |
|
$0.26 |
|
$0.28 |
|